The FINDRISC scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver disease
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, which includes changes from hepatic steatosis and nonalcoholic steatohepatitis to fibrosis and cirrhosis. Attempts to find noninvasive markers of liver fibrosis have led to a variety of scales...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2023-01-01
|
| Series: | Ожирение и метаболизм |
| Subjects: | |
| Online Access: | https://www.omet-endojournals.ru/jour/article/view/12832 |
| _version_ | 1797204528317071360 |
|---|---|
| author | A. S. Kuznetsova A. I. Dolgushina A. A. Selyanina T. A. Sokolova E. R. Olevskaya V. V. Genkel |
| author_facet | A. S. Kuznetsova A. I. Dolgushina A. A. Selyanina T. A. Sokolova E. R. Olevskaya V. V. Genkel |
| author_sort | A. S. Kuznetsova |
| collection | DOAJ |
| description | BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, which includes changes from hepatic steatosis and nonalcoholic steatohepatitis to fibrosis and cirrhosis. Attempts to find noninvasive markers of liver fibrosis have led to a variety of scales, diagnostic algorithms, and imaging techniques. Individual studies have analyzed the relationship between the FINDRISC scale and hepatic steatosis and concluded that this questionnaire can be used as part of population screening to identify individuals at risk for hepatic steatosis. However, our review of the literature did not reveal any clinical studies on the use and effectiveness of the FINDRISC in liver fibrosis screening.AIM: To evaluate diagnostic value of FINDRISC for liver fibrosis detection.MATERIALS AND METHODS: The study enrolled patients aged 40–60 years from unorganized outpatient population. The sample of patients was formed randomly according to the inclusion and noninclusion criteria. All patients were assessed with standard anthropometric parameters. The FINDRISC questionnaire was used. All patients underwent transabdominal ultrasound examination of the liver and transient liver elastometry. The degree of steatosis was evaluated using Hamaguchi ultrasound scale. RESULTS: The study included 100 patients. An increased risk of type 2 DM (≥7 points) was detected in 68% of patients using the FINDRISC scale. Liver steatosis was diagnosed in 41% of patients. Median values of hepatic elastic modulus by transient elastometry were 4.50 (4.00; 5.25) kPa. At the same time, liver elasticity modulus values ≥5.9 kPa were registered in 11 (11.0%) patients. When analyzing the array of sensitivity and specificity values using the ROC-curve, it was found that for the FINDRISC scale the maximum LR+ and the minimum LRvalues were observed when the number of points on the indicated scale exceeded 10. At this cutoff, the FINDRISC scale had a sensitivity of 81.8% and specificity of 61.8% for detecting liver fibrosis (liver modulus of elasticity ≥5.9 kPa). The scale was of good diagnostic value (AUC 0.699; 95% CI 0.530–0.815).CONCLUSION: In an unorganized sample of patients aged 40–60 years the FINDRISC can serve as a diagnostic tool for liver fibrosis and steatosis. Sum of FINDRISC scores >10 allowed to diagnose liver fibrosis (liver elastic modulus ≥5.9kPa) with sensitivity 81.8% and specificity 61.8%. The probability of absence of hepatic fibrosis with FINDRISC scale values <10 was 96.5%. |
| first_indexed | 2024-03-08T09:12:10Z |
| format | Article |
| id | doaj.art-56646f56ba1f4d6aa948f0a7a6cda425 |
| institution | Directory Open Access Journal |
| issn | 2071-8713 2306-5524 |
| language | English |
| last_indexed | 2024-04-24T08:36:39Z |
| publishDate | 2023-01-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Ожирение и метаболизм |
| spelling | doaj.art-56646f56ba1f4d6aa948f0a7a6cda4252024-04-16T16:16:14ZengEndocrinology Research CentreОжирение и метаболизм2071-87132306-55242023-01-0119325226010.14341/omet1283210939The FINDRISC scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver diseaseA. S. Kuznetsova0A. I. Dolgushina1A. A. Selyanina2T. A. Sokolova3E. R. Olevskaya4V. V. Genkel5South-Ural State Medical UniversitySouth-Ural State Medical University; Chelyabinsk Regional Clinical HospitalSouth-Ural State Medical University; Chelyabinsk City Clinical Hospital №1South-Ural State Medical UniversitySouth-Ural State Medical University; Chelyabinsk Regional Clinical HospitalSouth-Ural State Medical University; Chelyabinsk City Clinical Hospital №1BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, which includes changes from hepatic steatosis and nonalcoholic steatohepatitis to fibrosis and cirrhosis. Attempts to find noninvasive markers of liver fibrosis have led to a variety of scales, diagnostic algorithms, and imaging techniques. Individual studies have analyzed the relationship between the FINDRISC scale and hepatic steatosis and concluded that this questionnaire can be used as part of population screening to identify individuals at risk for hepatic steatosis. However, our review of the literature did not reveal any clinical studies on the use and effectiveness of the FINDRISC in liver fibrosis screening.AIM: To evaluate diagnostic value of FINDRISC for liver fibrosis detection.MATERIALS AND METHODS: The study enrolled patients aged 40–60 years from unorganized outpatient population. The sample of patients was formed randomly according to the inclusion and noninclusion criteria. All patients were assessed with standard anthropometric parameters. The FINDRISC questionnaire was used. All patients underwent transabdominal ultrasound examination of the liver and transient liver elastometry. The degree of steatosis was evaluated using Hamaguchi ultrasound scale. RESULTS: The study included 100 patients. An increased risk of type 2 DM (≥7 points) was detected in 68% of patients using the FINDRISC scale. Liver steatosis was diagnosed in 41% of patients. Median values of hepatic elastic modulus by transient elastometry were 4.50 (4.00; 5.25) kPa. At the same time, liver elasticity modulus values ≥5.9 kPa were registered in 11 (11.0%) patients. When analyzing the array of sensitivity and specificity values using the ROC-curve, it was found that for the FINDRISC scale the maximum LR+ and the minimum LRvalues were observed when the number of points on the indicated scale exceeded 10. At this cutoff, the FINDRISC scale had a sensitivity of 81.8% and specificity of 61.8% for detecting liver fibrosis (liver modulus of elasticity ≥5.9 kPa). The scale was of good diagnostic value (AUC 0.699; 95% CI 0.530–0.815).CONCLUSION: In an unorganized sample of patients aged 40–60 years the FINDRISC can serve as a diagnostic tool for liver fibrosis and steatosis. Sum of FINDRISC scores >10 allowed to diagnose liver fibrosis (liver elastic modulus ≥5.9kPa) with sensitivity 81.8% and specificity 61.8%. The probability of absence of hepatic fibrosis with FINDRISC scale values <10 was 96.5%.https://www.omet-endojournals.ru/jour/article/view/12832nonalcoholic fatty liver diseaseliver fibrosisfindriscnoninvasive diagnosis of liver fibrosis |
| spellingShingle | A. S. Kuznetsova A. I. Dolgushina A. A. Selyanina T. A. Sokolova E. R. Olevskaya V. V. Genkel The FINDRISC scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver disease Ожирение и метаболизм nonalcoholic fatty liver disease liver fibrosis findrisc noninvasive diagnosis of liver fibrosis |
| title | The FINDRISC scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver disease |
| title_full | The FINDRISC scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver disease |
| title_fullStr | The FINDRISC scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver disease |
| title_full_unstemmed | The FINDRISC scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver disease |
| title_short | The FINDRISC scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver disease |
| title_sort | findrisc scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver disease |
| topic | nonalcoholic fatty liver disease liver fibrosis findrisc noninvasive diagnosis of liver fibrosis |
| url | https://www.omet-endojournals.ru/jour/article/view/12832 |
| work_keys_str_mv | AT askuznetsova thefindriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease AT aidolgushina thefindriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease AT aaselyanina thefindriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease AT tasokolova thefindriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease AT erolevskaya thefindriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease AT vvgenkel thefindriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease AT askuznetsova findriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease AT aidolgushina findriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease AT aaselyanina findriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease AT tasokolova findriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease AT erolevskaya findriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease AT vvgenkel findriscscaleasariskassessmenttoolforliverfibrosisinpatientswithnonalcoholicfattyliverdisease |